Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix
    1.
    发明申请
    Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix 审中-公开
    包含固体或半固体基质的组合物和剂型

    公开(公告)号:US20090220596A1

    公开(公告)日:2009-09-03

    申请号:US11922609

    申请日:2006-06-22

    IPC分类号: A61K9/20 A61K9/10

    摘要: A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms.

    摘要翻译: 一种组合物,其包含固体或半固体基质,其具有均匀分散于其中的至少一种活性成分,所述基质包含至少一种药学上可接受的基质形成剂和1,3-双(内酰胺基) - 丁烷化合物,特别是1 ,3-双(吡咯烷酮-1-基) - 丁烷。 活性成分优选以固体状态分散在基质中。 基质形成剂优选为药学上可接受的聚合物。 该组合物可用于制备药物剂型。

    Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
    6.
    发明授权
    Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base 失效
    基于肝素,糖胺聚糖或类肝素的制剂,使用制剂和制剂基础

    公开(公告)号:US07393840B2

    公开(公告)日:2008-07-01

    申请号:US10296441

    申请日:2001-05-29

    IPC分类号: A61N31/747

    摘要: The present invention relates to formulations based on at least one heparin, glycosaminoglycan or heparinoid and on a formulation base with a lipid component and a polymer component. The use of this formulation as drug form for oral administration of at least one heparin, glycosaminoglycan or heparinoid, and also a process for producing the formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as drug form, advantageously using melt extrusion, are described. The lipid component advantageously has active ingredient-promoting properties, while the polymer component is soluble or swellable. At least parts of the lipid component are embedded in a polymer matrix, preferably in the form of a molecular dispersion. The formulations can form emulsions in water or aqueous liquids.

    摘要翻译: 本发明涉及基于至少一种肝素,糖胺聚糖或类肝素的制剂,以及具有脂质组分和聚合物组分的制剂基质。 使用这种制剂作为口服给药至少一种肝素,糖胺聚糖或类肝素的药物形式,以及通过混合制剂组分以形成塑料混合物并在适当时制备制剂作为药物来制备制剂的方法 描述了有利地使用熔体挤出的形式。 脂质组分有利地具有活性成分促进性质,而聚合物组分是可溶的或可溶胀的。 至少部分脂质组分嵌入聚合物基质中,优选以分子分散体的形式。 制剂可以在水或含水液体中形成乳液。

    SOLID DOSAGE FORM WITH A FILM CONTAINING AN ACTIVE SUBSTANCE, AS WELL AS ITS METHOD OF PRODUCTION
    9.
    发明申请
    SOLID DOSAGE FORM WITH A FILM CONTAINING AN ACTIVE SUBSTANCE, AS WELL AS ITS METHOD OF PRODUCTION 失效
    具有包含活性物质的电影的固体剂型,以及其生产方法

    公开(公告)号:US20100119583A1

    公开(公告)日:2010-05-13

    申请号:US12447506

    申请日:2007-11-12

    摘要: The present invention relates to a solid dosage form with at least one film (1), which contains an active substance at least in sections. The dosage form is characterized in that the concentration of active substance in film (1) or in the films has a gradient in a direction normal to the thickness of film (1). The invention further relates to a method of production of a solid dosage form with an active substance, in which at least one film (1) is produced, which contains an active substance at least in sections, with the concentration of active substance in film (1) or in the films having a gradient in the longitudinal direction of the film. This film is then formed to produce the dosage form.

    摘要翻译: 本发明涉及具有至少一个膜(1)的固体剂型,其至少包含活性物质的部分。 剂型的特征在于膜(1)中或膜中活性物质的浓度在垂直于膜(1)的厚度的方向上具有梯度。 本发明还涉及生产具有活性物质的固体剂型的方法,其中制备至少一种膜(1),其至少包含活性物质至少在膜中(活性物质在膜中的浓度) 1)或在膜的纵向具有梯度的膜中。 然后形成该膜以产生剂型。